German gov’t deals blow to Sanofi-Aventis’ Acomplia

Share this article:
Sanofi-Aventis said it intends to contest in court the decision by the German health ministry to classify anti-obesity drug Acomplia as a non-reimbursable drug. The ministry recommendation was published in the Official Journal of the Government, prompting an immediate response by the drug maker. “Sanofi-Aventis considers the proposed reimbursement classification of Acomplia as unjustified given the profile of the drug,” the firm said in a statement. Sanofi has argued that, since it helps lower a person's risk for developing diabetes and heart disease in addition to helping with weight loss, rimonabant should be covered under the state health insurance program.
Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.